Cancer Immunotherapy
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (28 December 2021) | Viewed by 8788
Special Issue Editor
Special Issue Information
Dear Colleagues,
The long-underestimated importance of T-cells in cancer elimination is now recognized and continues to expand. From engineering T-cells with a CAR or TCR, to modulating their function with immune checkpoint blockades or other molecules, dramatic successes in several patient populations justify continued mechanistic work on these subjects. Although durable responses exist, the fact that the majority of patients treated with immune therapies still relapse prompts the following questions: why some patients in each of these therapies relapse while others remain cancer-free? How can we overcome the limitations of current T-cell based therapies to provide long-lasting responses and cures to more patients? Further, how can we harness the potential of other immune cells to better recognize or eliminate cancers?
In this Special Issue, we invite research that highlights further potential advances in immune therapies, whether by direct modification of immune cells, development of novel immune modulators, or utilization of previously established therapies in new ways to further enhance antitumor immune effector function.
Dr. Carl DeSelm
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Immune checkpoint blockade
- CAR T-cells
- TCR therapy
- Cancer immunotherapy
- T-cell phenotype, exhaustion, or activation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
